MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Takeda Pharmaceutical Co Ltd ADR

Закрыт

СекторЗдравоохранение

15.19 1.47

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

14.97

Макс.

15.34

Ключевые показатели

By Trading Economics

Доход

-68B

24B

Продажи

-32B

1.1T

P/E

Средняя по отрасли

34.581

63.778

Прибыль на акцию

0.048

Дивидендная доходность

4.39

Рентабельность продаж

2.079

Сотрудники

49,281

EBITDA

-4.3B

380B

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

4.39%

2.39%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

47B

Предыдущая цена открытия

13.72

Предыдущая цена закрытия

15.19

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Takeda Pharmaceutical Co Ltd ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 янв. 2025 г., 11:02 UTC

Отчет

Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update

30 янв. 2025 г., 07:53 UTC

Отчет

Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO

28 янв. 2025 г., 00:03 UTC

Популярные акции

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

31 окт. 2024 г., 07:27 UTC

Отчет

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance -- Update

31 окт. 2024 г., 06:44 UTC

Отчет

Takeda Pharmaceutical Posts Quarterly Net Profit, Raises Guidance

31 июл. 2024 г., 07:19 UTC

Отчет

Takeda Pharmaceutical's First-Quarter Profit Rose on Higher Revenue -- Update

31 июл. 2024 г., 06:29 UTC

Отчет

Takeda Pharmaceutical Reports Rise in First-Quarter Net Profit on Higher Revenue

17 июн. 2024 г., 13:34 UTC

Главные движущие силы рынка

Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback

13 мая 2024 г., 11:26 UTC

Главные движущие силы рынка

AC Immunity Shares Soar on Exclusive License Deal with Takeda

9 мая 2024 г., 07:37 UTC

Отчет

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update

9 мая 2024 г., 07:08 UTC

Отчет

Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss

30 янв. 2025 г., 07:12 UTC

Отчет

Correct: Takeda: U.S. Business Unit President Julie Kim to Become CEO in June 2026, Not June

30 янв. 2025 г., 07:08 UTC

Отчет

Takeda: U.S. Business Unit President Julie Kim to Become CEO in June

30 янв. 2025 г., 06:42 UTC

Отчет

Takeda 3Q Rev Y1.144T Vs. Y1.111T >4502.TO

30 янв. 2025 г., 06:40 UTC

Отчет

Takeda 3Q Net Y23.8B Vs. Net Y105.7B >4502.TO

30 янв. 2025 г., 06:36 UTC

Отчет

Takeda: to Discontinue Soticlestat Development Program

30 янв. 2025 г., 06:34 UTC

Отчет

Takeda: Program May Repurchase Up to 1.8% of Outstanding Shares

30 янв. 2025 г., 06:32 UTC

Отчет

Takeda: To Buy Back Up to Y100B of Own Shares from Feb. 17 to May 31

30 янв. 2025 г., 06:31 UTC

Отчет

Takeda Pharmaceutical Raises Revenue, Net-Profit Views for FY Ending March

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical Sees FY Net Y118.00B

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical Sees FY Net Y118.00B

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical Raises FY Dividend to Y196.00

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical 9-Mos EPS Y133.71 Vs EPS Y94.10

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical 9-Mos Pretax Pft Y282.38B Vs Pft Y100.31B

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical 9-Mos Oper Pft Y417.52B Vs Pft Y224.14B

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical 9-Mos Rev Y3.53T Vs Y3.21T

30 янв. 2025 г., 06:30 UTC

Отчет

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

Сравнение c конкурентами

Изменение цены

Takeda Pharmaceutical Co Ltd ADR Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

0

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

14.89 / 15.155Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

Strong Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.